💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, fast-growing business, reasonably priced.
IPCA Laboratories is scored on the pharma / healthcare framework. It keeps a healthy 12.1% of every rupee of sales as net profit. Cash broadly tracks reported profit (CFO/PAT 0.96×). Free cash flow is worth about 1.8% of its market value.
Over the last 3 years revenue compounded at 16%/yr and profit at 34%/yr. Book value itself has compounded 17%/yr — the hallmark of a genuine compounder. Return on equity is a healthy 14.2%. In the latest quarter profit grew 37% versus the prior quarter.
At 44× earnings, the stock sits at the 20th percentile of its own 3.5-year range — the cheap end of where it has historically traded. Today's price implies ~17%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 36.15 | 37.43 | better |
| P/B | 6.16 | 8.2 | better |
| EV/EBITDA | 21.67 | 19.3 | worse |
| ROE | 14.15 | 21.23 | worse |
| ROCE | 18.58 | 23.75 | worse |
| ROA | 11.15 | 12.84 | worse |
| Quick Ratio | 1.58 | 2.21 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 37.6 | 5.5 | 13.7% |
| Divis Laboratories | 84.5 | 14.7 | 15.3% |
| Torrent Pharmaceuticals | 86.7 | 22.2 | 25.5% |
Revenue has grown every year across all 4 financial years shown. 16% CAGR over 3 years — steady double-digit compounder. Growth is decelerating — latest year grew slower than the year before.
Net profit has risen every year — the hallmark of a compounder. Profit is growing faster than revenue (34% vs 16%) — margin expansion is at work. The latest year saw a +51% swing — check if it's a one-off or structural.
Operating margin has expanded from 12% to 16% — the business is keeping more of each rupee earned.
ROE at 13% — a respectable return on shareholder capital.
EPS has grown every year — each share earns more than the last, consistently. 34% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 13% sequentially — momentum is building.
Profit jumped 37% QoQ — check if this is operating leverage or a one-off item. Quarterly net margins are expanding (11% → 15%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.5y median.
Promoters at 44.7% — dispersed ownership; institutional flows drive the stock.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.